Marksans Pharma (MARKSANS) | Stock Overview & Key Data
Marksans Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹165.45
High: ₹168.06
on October 3, 2025
52 Week Range
Low: ₹162.51
High: ₹358.70
on September 26, 2025
on December 2, 2024
All-Time High: ₹358.70 on December 2, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR77.1B
EPS
7.73
P/E Ratio (TTM)
21.35
Forward P/E
13.83
P/B Ratio
3.03
PEG Ratio
-0.62
Div. Yield
0.62%
ROE
15.29%
Beta
1.226
Debt to Equity
12.93
Financial Highlights
Profitability
Gross Margin
57.77%
Operating Margin
12.42%
Profit Margin
13.20%
Returns and Earnings
Return on Assets (TTM)
11.75%
Return on Equity (TTM)
15.29%
EBITDA
INR5.6B
Net Income (TTM)
INR3.5B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR58.53
Quarterly Revenue Growth (YoY)
5.00%
Quarterly Earnings Growth (YoY)
-34.30%
Dividend Information
Last 12-Month Dividend
₹1.40
Current Dividend Yield
0.62%
3-Year Average Dividend Yield
0.40%
3-Year Average Annual Dividend
₹0.72
3-Year Total Dividends
₹2.15
Ex-Dividend Date
August 1, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Marksans Pharma MARKSANS | 77.07B Mid-cap | -2.00% | -0.42% | -35.52% | -24.91% | -45.29% | -42.49% | 252.74% | 211.24% |
| GlaxoSmithKline GLAXO | 458.57B Large-cap | -1.79% | -3.96% | -19.57% | -3.58% | 20.84% | -1.52% | 93.34% | 80.13% |
| Pfizer PFIZER | 231.58B Large-cap | 2.92% | 0.31% | -9.61% | 27.62% | -2.95% | -8.29% | 16.04% | 2.57% |
| Sanofi India Limited SANOFI | 110.69B Mid-cap | -5.70% | -7.96% | -24.04% | -19.50% | -22.71% | -31.49% | -20.52% | -45.48% |
| Sanofi Consumer SANOFICONR | 108.89B Mid-cap | -5.13% | -6.70% | -12.40% | -1.24% | -3.25% | -4.79% | -3.15% | -3.15% |
| Senores SENORES | 32.95B Small-cap | -4.06% | -1.93% | 18.10% | 22.01% | 20.44% | 20.06% | 20.06% | 20.06% |
Ownership & Short Interest
Insider Ownership
46.37%
Institutional Ownership
16.90%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
1M
Average 90-Day Volume
1M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MARKSANS's 52-week high and low?
- In the last 52 weeks, Marksans Pharma reached a high of ₹358.70 (on December 2, 2024) and a low of ₹162.51 (on September 26, 2025).
- What is the market cap and P/E ratio for MARKSANS?
- Curious about Marksans Pharma's size and valuation? Its market capitalization stands at 77.07B. When it comes to valuation, the P/E ratio (trailing twelve months) is 21.35, and the forward P/E (looking ahead) is 13.83.
- Does MARKSANS pay dividends? If so, what's the yield?
- Yes, Marksans Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.62%, and the company has paid an average of ₹0.72 per share annually over the past 3 years.
- Who are Marksans Pharma's main competitors or similar companies to consider before investing?
When looking at Marksans Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return GlaxoSmithKline
GLAXO458.57B Healthcare Drug Manufacturers - General -1.52% 93.34% Pfizer
PFIZER231.58B Healthcare Drug Manufacturers - General -8.29% 16.04% Sanofi India Limited
SANOFI110.69B Healthcare Drug Manufacturers - General -31.49% -20.52% Sanofi Consumer
SANOFICONR108.89B Healthcare Drug Manufacturers - General -4.79% -3.15% Senores
SENORES32.95B Healthcare Drug Manufacturers - General 20.06% 20.06% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Marksans Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Marksans Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 15.29%, the Debt to Equity ratio from the most recent quarter is 12.93, and its Gross Profit Margin stands at 57.77%.
- What is the recent revenue and earnings growth for MARKSANS?
- Looking at Marksans Pharma's growth, its revenue over the trailing twelve months (TTM) was INR27B. Compared to the same quarter last year (YoY), quarterly revenue grew by 5.00%, and quarterly earnings saw a YoY growth of -34.30%.
- How much of MARKSANS stock is held by insiders and institutions?
- Wondering who owns Marksans Pharma stock? Company insiders (like executives and directors) hold about 46.37% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 16.90%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.